Skip to main content
Douglas Tremblay, MD, Hematology, New York, NY, The Mount Sinai Hospital

DouglasAllenTremblayMD

Hematology New York, NY

Physician

Dr. Tremblay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tremblay's full profile

Already have an account?

Education & Training

  • Icahn School of Medicine at Mount Sinai (Bronx)
    Icahn School of Medicine at Mount Sinai (Bronx)Residency, Internal Medicine, 2014 - 2017
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2014

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2015 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Inductee Alpha Omega Alpha Honor Medical Society

Publications & Presentations

PubMed

Abstracts/Posters

  • Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients
    Douglas Tremblay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis
    Douglas Tremblay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
    Douglas Tremblay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Utility of Thrombophilia Testing in Portal Vein Thrombosis in a Large Single Institutional Cohort 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • FDA Approves Momelotinib (Ojjaara) for Myelofibrosis Patients with Anemia
    FDA Approves Momelotinib (Ojjaara) for Myelofibrosis Patients with AnemiaSeptember 20th, 2023

Hospital Affiliations